Profiling biopharmaceutical deciding properties of absorption of lansoprazole enteric-coated tablets using gastrointestinal simulation technology.

The aim of the present study was to correlate in vitro properties of drug formulation to its in vivo performance, and to elucidate the deciding properties of oral absorption. Gastrointestinal simulation technology (GST) was used to simulate the in vivo plasma concentration-time curve and was implemented by GastroPlus™ software. Lansoprazole, a typical BCS class II drug, was chosen as a model drug. Firstly, physicochemical and pharmacokinetic parameters of lansoprazole were determined or collected from literature to construct the model. Validation of the developed model was performed by comparison of the predicted and the experimental plasma concentration data. We found that the predicted curve was in a good agreement with the experimental data. Then, parameter sensitivity analysis (PSA) was performed to find the key parameters of oral absorption. The absorption was particularly sensitive to dose, solubility and particle size for lansoprazole enteric-coated tablets. With a single dose of 30 mg and the solubility of 0.04 mg/ml, the absorption was complete. A good absorption could be achieved with lansoprazole particle radius down to about 25 μm. In summary, GST is a useful tool for profiling biopharmaceutical deciding properties of absorption of lansoprazole enteric-coated tablets and guiding the formulation optimization.

[1]  Lawrence X. Yu,et al.  Utility of Physiologically Based Absorption Modeling in Implementing Quality by Design in Drug Development , 2011, The AAPS Journal.

[2]  Thierry Lavé,et al.  Predicting Pharmacokinetic Food Effects Using Biorelevant Solubility Media and Physiologically Based Modelling , 2006, Clinical pharmacokinetics.

[3]  T. Makino,et al.  Stabilization of a new antiulcer drug (Lansoprazole) in the solid dosage forms , 1992 .

[4]  F. Vrečer,et al.  The influence of gastric emptying kinetics on the drug release from enteric coated pellets in fasted state: an in vitro/in vivo correlation. , 2012, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[5]  Christos Reppas,et al.  Biorelevant in vitro dissolution testing of products containing micronized or nanosized fenofibrate with a view to predicting plasma profiles. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[6]  Xinyuan Zhang,et al.  The role of predictive biopharmaceutical modeling and simulation in drug development and regulatory evaluation. , 2011, International journal of pharmaceutics.

[7]  F. Vrečer,et al.  Preformulation Investigation of the Novel Proton Pump Inhibitor Lansoprazole , 2000, Drug development and industrial pharmacy.

[8]  Arik Dahan,et al.  A win-win solution in oral delivery of lipophilic drugs: supersaturation via amorphous solid dispersions increases apparent solubility without sacrifice of intestinal membrane permeability. , 2012, Molecular pharmaceutics.

[9]  G L Amidon,et al.  Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption. , 1996, Advanced drug delivery reviews.

[10]  K. Higaki,et al.  Analysis and prediction of absorption behavior of colon-targeted prodrug in rats by GI-transit-absorption model. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[11]  G. Amidon,et al.  The solubility-permeability interplay: mechanistic modeling and predictive application of the impact of micellar solubilization on intestinal permeation. , 2011, Molecular pharmaceutics.

[12]  L. Schanker On the mechanism of absorption of drugs from the gastrointestinal tract. , 1960, Journal of medicinal and pharmaceutical chemistry.

[13]  J. Horn,et al.  The proton-pump inhibitors: similarities and differences. , 2000, Clinical therapeutics.

[14]  A. Dahan,et al.  The solubility-permeability interplay when using cosolvents for solubilization: revising the way we use solubility-enabling formulations. , 2012, Molecular pharmaceutics.

[15]  Neil Parrott,et al.  Applications of physiologically based absorption models in drug discovery and development. , 2008, Molecular pharmaceutics.

[16]  B Agoram,et al.  Predicting the impact of physiological and biochemical processes on oral drug bioavailability. , 2001, Advanced drug delivery reviews.

[17]  Siling Wang,et al.  Relationship between dissolution and bioavailability for nimodipine colloidal dispersions: the critical size in improving bioavailability. , 2012, International journal of pharmaceutics.

[18]  Gordon L. Amidon,et al.  Estimating the Fraction Dose Absorbed from Suspensions of Poorly Soluble Compounds in Humans: A Mathematical Model , 1993, Pharmaceutical Research.

[19]  Kazuhide Yamamoto,et al.  Proton Pump Inhibitor Dose-Related Healing Rate of Artificial Ulcers after Endoscopic Submucosal Dissection: A Prospective Randomized Controlled Trial , 2011, Digestion.

[20]  L. Schanker Absorption of drugs from the rat colon. , 1959, The Journal of pharmacology and experimental therapeutics.

[21]  Martin Kuentz,et al.  A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[22]  M. Odomi,et al.  Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[23]  L. A. Fenu,et al.  The Prediction of Drug Metabolism, Tissue Distribution, and Bioavailability of 50 Structurally Diverse Compounds in Rat Using Mechanism-Based Absorption, Distribution, and Metabolism Prediction Tools , 2007, Drug Metabolism and Disposition.

[24]  A. Noyes,et al.  The rate of solution of solid substances in their own solutions , 1897 .

[25]  H. Lennernäs,et al.  Oral Drug Absorption: Prediction and Assessment , 2000 .

[26]  Jennifer B Dressman,et al.  Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system. , 2004, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[27]  Filippos Kesisoglou,et al.  Understanding the Effect of API Properties on Bioavailability Through Absorption Modeling , 2008, The AAPS Journal.

[28]  Gordon L Amidon,et al.  The solubility-permeability interplay in using cyclodextrins as pharmaceutical solubilizers: mechanistic modeling and application to progesterone. , 2010, Journal of pharmaceutical sciences.

[29]  Mitra Mosharraf,et al.  The effect of particle size and shape on the surface specific dissolution rate of microsized practically insoluble drugs , 1995 .

[30]  L. A. Fenu,et al.  Prediction of Human Pharmacokinetics Using Physiologically Based Modeling: A Retrospective Analysis of 26 Clinically Tested Drugs , 2007, Drug Metabolism and Disposition.

[31]  J. Crison,et al.  A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability , 1995, Pharmaceutical Research.

[32]  Thierry Lavé,et al.  Prediction of intestinal absorption: comparative assessment of GASTROPLUS and IDEA. , 2002, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[33]  R. J. Hintz,et al.  The effect of particle size distribution on dissolution rate and oral absorption , 1989 .

[34]  Raimar Löbenberg,et al.  Computer simulations using GastroPlus to justify a biowaiver for etoricoxib solid oral drug products. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[35]  P J Sinko,et al.  Development of predictive pharmacokinetic simulation models for drug discovery. , 2000, Journal of controlled release : official journal of the Controlled Release Society.